FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

(2013) C. C. Smith et al.   BLOOD

Prevalence and Prognostic Significance of FLT3 Gene Mutations in Patients with Acute Leukaemia: Analysis of Patients from the Shanghai Leukaemia Co-operative Group

(2013) W Wang et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

(2013) C Albers et al.   LEUKEMIA

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

(2012) A. Sexauer et al.   BLOOD

How I treat newly diagnosed chronic phase CML

(2012) J. Cortes et al.   BLOOD

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia

(2012) Joanna Schiller et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

(2012) Susanne Schnittger et al.   GENES CHROMOSOMES & CANCER

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

(2012) A. Nazha et al.   HAEMATOLOGICA

Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm—Combined Prospective Analysis by the German AML Intergroup

(2012) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

(2012) S K Metzelder et al.   LEUKEMIA

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

(2012) David A. Macdonald et al.   LEUKEMIA & LYMPHOMA

Molecular analysis of differentFLT3-ITD mutations in acute myeloid leukemia

(2012) Olga Blau et al.   LEUKEMIA & LYMPHOMA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution

(2011) Amy E. DeZern et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib

(2011) Manish Sharma et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Rethinking bioactivity of FLT3 inhibitors

(2011) T. Fischer   BLOOD

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

FLT3/ITD AML and the law of unintended consequences

(2011) M. Levis   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

(2011) A. Parmar et al.   CANCER RESEARCH

Survey of Activated FLT3 Signaling in Leukemia

(2011) Ting-lei Gu et al.   PLoS One

Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells

(2010) Friedrich Stölzel et al.   ANNALS OF HEMATOLOGY

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

(2010) M Michael et al.   BRITISH JOURNAL OF CANCER

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

(2010) Michael Crump et al.   LEUKEMIA & LYMPHOMA

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

(2009) L. Ades et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

(2009) S. Metzelder et al.   BLOOD

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

(2009) F. Breitenbuecher et al.   BLOOD

FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

(2009) N. von Bubnoff et al.   CANCER RESEARCH

Mechanisms of resistance to FLT3 inhibitors

(2009) S. Haihua Chu et al.   DRUG RESISTANCE UPDATES

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers

(2009) Nancy L. Lewis et al.   JOURNAL OF CLINICAL ONCOLOGY

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects

(2008) Ophelia Q P Yin et al.   CLINICAL PHARMACOKINETICS

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia

(2008) A Agarwal et al.   LEUKEMIA

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE